Stock Detail
CHELSEA THERAPEUTICS INTERNATIONAL LTD
Sector: Biotechnology
Latest Quote @ Sun May 5 16:14:24 (15 min delayed)
| N/A |
N/A |
$1.88 |
-0.01 |
-0.53% |
|
Last Day's Data
| $1.88 |
$1.92 |
$0.00 |
0.00% |
0.00 |
$1.89 |
| $1.88 |
$1.86 |
356,573.00 |
126.11M |
579,534.00 |
0.00 |
Pivot Table
| R2 |
R1 |
Pivot |
S1 |
S2 |
| 1.95 |
1.92 |
1.89 |
1.86 |
1.83 |
Stock Profile
Chelsea Therapeutics International, Ltd., a development stage pharmaceutical company, focuses to acquire and develop products for the treatment of various human diseases. The company develops prescription products for multiple autoimmune disorders, including rheumatoid arthritis, psoriasis, inflammatory bowel disease, and cancer. It also develops therapeutic agent for the treatment of neurogenic orthostatic hypotension and related conditions, and diseases. In addition, the company develops platform technologies that consist of a portfolio of molecules for the treatment of various autoimmune/inflammatory diseases, and I-3D portfolio, a dihydroorotate dehydrogenase inhibiting compound. Chelsea Therapeutics' product in development includes CH-1504, an orally available molecule for the treatment of rheumatoid arthritis, psoriasis, inflammatory bowel disease, psoriatic arthritis, and cancer. The company was incorporated in 2002 and is based in Charlotte, North Carolina.
